Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 495 results for "Tecfidera"

Tecfidera Continues to Be Key Revenue Driver for Biogen in 1Q16

Strong Product Portfolio Drove Biogen's 1Q16 Profit Margins ( Continued from Prior Part ) Tecfidera performance By the end of 1Q16, Biogen's (BIIB) leading multiple sclerosis (or MS) drug, Tecfidera, had treated about 190,000 multiple ... Yahoo! Finance UK and Ireland, 4 days ago
Tysabri Reports Strong Patient Growth in 1Q16 Yahoo! Finance UK and Ireland, 1 day ago
Biogen's Hemophilia Drugs Continue to Capture Market Share in 1Q16 Yahoo! Finance UK and Ireland, 3 days ago
European Pharmaceutical Review

TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness

-- More than Half of Newly Diagnosed MS Patients Taking TECFIDERA Remained Free of Relapse and Disability Progression Over Six Years -- -- New Analyses Show TECFIDERA Associated with Significantly Lower ARR Relative to Glatiramer Acetate, ...
 Bloomberg1 week ago Tecfidera demonstrates sustained efficacy in RRMS studies  European Pharmaceutical Review1 week ago TECFIDERA data confirm strong and sustained efficacy in newly diagnosed MS patients and real-world effectiveness  Medical News Today1 week ago Biogen Reports TECFIDERA Data Confirms Strong, Sustained Efficacy in Newly-Diagnosed MS Patients  Morningstar.com1 week ago

Biogen Q1 profits rise boosted by Tecfidera sales

Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter profit driven by sales ofmultiple-sclerosis drug Tecfidera. The biotech firm reported profit of $970.9 million, or $4.43 a ...
 Pharmafile1 week ago Biogen Profit Climbs On Higher Sales of Multiple-Sclerosis Drug  Nasdaq1 week ago Tecfidera sales growth fuels Biogen's rise in first-quarter revenue, profit  FirstWord Pharma1 week ago BIOGEN : Profit Climbs, Helped by Stronger Sales of Tecfidera  4 Traders1 week ago

MERCK KGAA : EMD Serono to Present Data Assessing Comparative Effectiveness of Rebif® interferon beta-1a vs. TECFIDERA® dimethyl fumurate at AAN Annual Meeting

By a News Reporter-Staff News Editor at Clinical Trials Week -- EMD Serono, the North America biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced that clinical and real-world data about Rebif(®) (interferon beta-1a), will be ...
 4 Traders1 week ago EMD Serono to Present Data Assessing Comparative Effectiveness of Rebif® interferon beta-1a vs. TECFIDERA® dimethyl fumurate at AAN Annual Meeting  Equities.com1 week ago

Tecfidera Revenues Expected to Boost Biogen's 2016 Valuations

Drugs That Could Boost Biogen's Valuations in 2016 ( Continued from Prior Part ) Tecfidera revenues Biogen Idec (BIIB) saw a sudden revenue decline for Tecfidera in 2015. But demand for the drug in the US market is expected to remain stable ...
 Yahoo! Singapore2 months ago Global Autoimmune Drugs Market 2016-2020  Research and Markets1 month ago Autoimmune Drugs Market to Grow 5.57% CAGR 2016 to 2020  Before It's News1 month ago Remyelination Research for MS Could Boost Biogen's Valuations  Yahoo! 7 Finance1 month ago
Pharma Letter

Biogen sees European Tecfidera patent revoked15-03-2016

The European Patent Office (EPO) last week revoked US biotech major Biogen's (Nasdaq: BIIB) European Patent EP2137537, a method of use patent concerning its blockbuster multiple sclerosis drug Tecfidera (dimethyl fumarate). Biogen said that it ...
 Pharma Letter1 month ago EU revokes one of the patents on Biogen blockbuster Tecfidera  FiercePharma1 month ago Biogen's Best-Selling Drug Loses Patent In EU, Says Cowen  Barchart1 month ago

TECFIDERA® data highlights benefit of early treatment in relapsing-remitting multiple sclerosis

Biogen present new TECFIDERA (dimethyl fumarate) research at the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada. The data presented supports the value of dimethyl fumarate in the treatment of patients with ...
 Hospital Pharmacy Europe1 day ago

Biogen's controversial Tecfidera ad is about to meet its end

Biogen's DTC ad for multiple sclerosis pill Tecfidera has garnered its fair share of criticism from patients who say it's unrealistic. But that didn't stop the TV commercial from getting the job done, the company says--and now that it has, it's on ...
 CPhI.cn1 day ago Biogen's 'active woman' Tecfidera ad will go off air soon  BioPharma Dive1 day ago
Proactive Investors USA

Biogen profit beats estimates as costs fall, Tecfidera sales rise

* Tecfidera sales rise 15 pct to $946 mln * Total costs down 6.2 pct * 1st-qtr profit $4.79/shr vs est. $4.47 (Adds details, analysts' comment; updates shares) By Amrutha Penumudi April 21 (Reuters) - Biogen Inc reported a better-than-expected ...
 Sharenet1 week ago Biogen tops Wall Street estimates for quarter  Proactive Investors USA1 week ago Cost cutting helps Biogen top Wall Street estimates for quarter  Sharenet1 week ago UPDATE 3-Cost cutting helps Biogen top Wall Street estimates for quarter  Reuters UK1 week ago

Fingolimod Easier to Swallow Than Dimethyl Fumarate?

Fingolimod (Gilenya, Novartis) was better tolerated than dimethyl fumarate (Tecfidera, Biogen) in a 2-year comparison of the oral multiple sclerosis
 RxList1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Tecfidera
Get updated on latest news & your favorite topics right in your inbox!
More     Less